Managing hypertension in diabetic patients – focus on trandolapril/verapamil combination

References

• Abbott LaboratoriesIsoptin SR (verapamil HCL) US prescribing information2002aNorth Chicago (IL)Abbott Laboratories
   Google Scholar
• Abbott LaboratoriesTarka 180/2 mg capsules: summery of product characteristics 2002 [online]2002b Accessed 2006 Jun 22. URL: http//emc.medicine.org.uk
   Google Scholar
• Abbott Laboratories, North Chicago (IL), USATARKA® (trandolapril/verapamil hydrochloride ER tablets): prescribing information 2003 [online]2003a Accessed 2006 Jun 22. URL: http//www.abbott.com/corporate/product_list.cfm
   Google Scholar
• Abbott Laboratories, North Chicago (IL), USAMavik® (trandolapril tablets): prescribing information 2003 [online]2003b Accessed 2006 Jun 22. URL: http//www.rxabbott.com/pdf/mavik.pdf
   Google Scholar
• AbuissaHBellDSHO’KeefeJHJrStrategies to prevent type 2 diabetesCurr Med Res Opin20052111071416004680
   PubMed Web of Science ®Google Scholar
• AlderAIStevensRJManleySEDevelopment and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney Int2003632253212472787
   PubMed Web of Science ®Google Scholar
• AldermanMHThe return on INVESTJAMA200329028596114657071
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationHypertension management in adults with diabetesDiabetes Care200427s65714693929
   PubMedGoogle Scholar
• ArnerPWadeAEngfeldtPPharmacokinetics and Pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertensionJ Cardiovasc Pharmacol199423Suppl 4s449
   Google Scholar
• BakrisGLBurnhillBWSadlerRTreatment of arterial hypertension in diabetic humans: importance of therapeutic selectionKidney Int19924191219
   Google Scholar
• BakrisGLGaxiolaEMesserliFHClinical outcome in the diabetes cohort on International Verapamil SR-Trandolapril studyHypertension2004446374215381674
   PubMed Web of Science ®Google Scholar
• BakrisGLWeirMRDeQuattroVEffects of an ACE inhibitor/calcium antagonist combination on protenuria in diabetic nephropathyKidney Int199854128399767545
   PubMed Web of Science ®Google Scholar
• BakrisGLWeirMRShanifarSEffects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL studyArch Intern Med200316315556512860578
   PubMed Web of Science ®Google Scholar
• BeckmanJACreagerMALibbyPDiabetes and atherosclerosis: Epidemiology, pathophysiology, and managementJAMA200228725708112020339
   PubMed Web of Science ®Google Scholar
• BerlTHunsickerLGLewisJBfor the Collaborative Study GroupCardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyAnn Intern Med2003138542912667024
   PubMed Web of Science ®Google Scholar
• BerneCPollareTLithellHEffects of antihypertensive treatment on insulin sensitivity with special reference to ACE-inhibitorsDiabetes Care199114Suppl 439471748056
   PubMed Web of Science ®Google Scholar
• BevanEGMcInnesGTAldigierJCEffect of renal function on the pharmacokinetics and pharmacodynamics of trandolaprilBr J Clin Pharmacol199335128358443030
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDRENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med2001345861911565518
   PubMed Web of Science ®Google Scholar
• Breithaupt-GroglerKGerhardtGLehmannGBlood presuure and aortic elastic properties: verapamil SR/trandolapril compared to metoprolol/hydrochlorthiazide combination thearapyInt J Clin Pharmacol Ther199836425319726695
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRJoint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension200342120612514656957
   PubMed Web of Science ®Google Scholar
• ChoiKLBakrisGLHypertension treatment Guidelines: practical implicationsSemin Nephrol20052519820916202692
   PubMed Web of Science ®Google Scholar
• CurbJDPresselSLCutlerJAEffect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetes patients with isolated systolic hypertension. Systolic Hyperetension in the Elderly Program Cooperative Research GroupJAMA19962761886928968014
   PubMed Web of Science ®Google Scholar
• DanielsonBQuerinSLaRochellePPharmacokinetic and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjectsJ Cardiovasc Pharmacol199423Suppl 4s5097527102
   PubMedGoogle Scholar
• de leeuwPWNotterTZillesPComparison of different fixed antihypertensive combination drugs: a double blind, placebo-controlled, parallel group studyJ Hypertens19971587919050975
   PubMed Web of Science ®Google Scholar
• DeQuattroVLeeDTrandolapril Study GroupFixed dose combination therapy with trandolapril and verapamil SR is effective in primary hypertensionAm J Hypertens199710138s45s9231890
   PubMed Web of Science ®Google Scholar
• DillonJJThe quantitative relationship between treated blood pressure and progression of diabetic renal diseaseAm J Kidney Dis1993227988028250025
   PubMed Web of Science ®Google Scholar
• DinneenSFGersteinHCThe association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literatureArch Intern Med19971571413189224218
   PubMed Web of Science ®Google Scholar
• FernándezRPuigJGRodríguez-PérezJCEffect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind studyJ Hum Hypertens2001158495611773987
   PubMed Web of Science ®Google Scholar
• FlackJMSowersJREpidemiologic and clinical aspects of insulin resistance and hyperinsulinemiaAm J Med19919111S21S1867224
   PubMed Web of Science ®Google Scholar
• GallMAHougaardPBorch-JohnsenKRisk factors for development of incipient and overt diabetic nephropathyin patients with non insulin dependant diabetes mellitus: prospective observational studyBMJ1997314783889080995
   PubMed Web of Science ®Google Scholar
• HaansoonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT study groupLancet19983511755629635947
   PubMed Web of Science ®Google Scholar
• HaegertAMSwalesJDThe combination of verapamil and captopril in the treatment of essential hypertensionPharmacotherapeutica198751
   Google Scholar
• HansenJFHangerupLSigurdBCardiac events rate after myocaridal infarction in patients treated with verapamil and trandolapril versus trandolapril aloneAm J Cardiol199715738419070551
   PubMedGoogle Scholar
• HarrisMIFlegalKMCowieCCPrevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994Diabetes Care199821518249571335
   PubMed Web of Science ®Google Scholar
• HolzgreveHNakovRBeckKJankaHUAntihypertensive therapy with verapamil sr plus trandolapril versus atenolol plus chlorthalidone on glycemic controlAm J Hypertens200316381612745200
   PubMed Web of Science ®Google Scholar
• Hypertension in Diabetes Study (HDS)Prevalence of hypertension in newly presenting type 2 diabetic patients and the association of risk factors for cardiovascular and diabetic complicatinsJ Hypertens199311309178387089
   PubMed Web of Science ®Google Scholar
• KalbergeBEAndrupMOdenAon behalf of the Swidish Tarka TrialistsEfficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertensionBlood Press20009140510855738
   PubMed Web of Science ®Google Scholar
• LenfantBMaurenMBryceTTrandolapril: Pharmacokinetics of single oral dose in healthy male volunteersJ Cardiovasc Pharmacol199423Suppl 4s23843
   Google Scholar
• ManciaGCooper-DeHoffRMHewkinAAssociation of BP control and frequency of mortality and morbidity in hypertensive patients with CAD - The International Verapamil SR-Trandolapril Study [abstract no. p-229]Am J Hypertens200415116a
   Google Scholar
• MogensenCEProgression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatmentScand J Clin Lab Invest1976363838959756
   PubMed Web of Science ®Google Scholar
• MogensenCEMicroalbuminuria predicts clinical proteiuria and early mortality in maturity-onset diabetesN Engl J Med1984310356606690964
   PubMed Web of Science ®Google Scholar
• MuijsersRBRCuranMPErryCMFixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertensionDrugs20026225396712421112
   PubMed Web of Science ®Google Scholar
• National Kidney FoundationK/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratificationAm J Kidney Dis200239Suppl 1S126611904577
   PubMed Web of Science ®Google Scholar
• NelsonRGKnowlerWCPettittDJAssessing risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimenArch Inttrn Med199115117615
   PubMedGoogle Scholar
• PapineMDHandbergEMCooper-DeHoffRMA calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil SR-Trandolapril Study: a randomized controlled trialJAMA200329028051614657064
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJThe effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013458707811565519
   PubMed Web of Science ®Google Scholar
• PernegerTVBrancatiFWheltonPKEnd-stage renal disease attributable to diabetes mellitusAnn Intern Med1994121912187978716
   PubMed Web of Science ®Google Scholar
• PohlMABlumenthalSCordonnierDJIndependent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitationsJ Am Soc Nephrol20051630273716120823
   PubMed Web of Science ®Google Scholar
• RaynoldsNAWagstaffAJKeamSJTrandolapril/verapamil sustained released: a review of its use in the treatment of Eessential hypertensionDrugs2005651893191416114984
   PubMed Web of Science ®Google Scholar
• ReidLDTuethMJHandbergEA study of antihypertensive drug and depressive symptoms (SADD-Sx) in patients treated with calcium antagonist versus an atenolol hyepretension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST)Psychosom Med20056739840615911902
   PubMed Web of Science ®Google Scholar
• RemuzziGMaciaMRuggenentiPPrevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT studyJ Am Soc Nephrol200617S90716565256
   PubMed Web of Science ®Google Scholar
• RomosFBaglovoHSanchezRComparative double blind study at fixed dose of trandolapril+verapamil vs. atenolol+chorthalidon in mild to moderate hypertensive patients [abstract no. p3185]J Hypertens200119Supp 12s236
   Google Scholar
• RuggenentiPFassiAIlievaAPfor the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) InvestigatorsPreventing microalbuminuria in type 2 diabetesN Engl J Med200435119415115516697
   PubMed Web of Science ®Google Scholar
• RuggenentiPPernaAGanevaMImpact of blood pressure control and ace inhibitor therapy on newly onset microalbuminuria in type 2 diabetes: a post-hoc analysis of the BENEDICT trialJ AM Soc Nephrol20061734728117082240
   PubMed Web of Science ®Google Scholar
• RuggenentiPRemuzziGTime to abandon microalbuminuria?Kidney Int20067012142216871239
   PubMed Web of Science ®Google Scholar
• RuilopeLMDissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomised double-blind trialJ Hypertens2002207293711910310
   PubMed Web of Science ®Google Scholar
• RuilopeLMUsanLSeguraJIntervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) studyJ Hypertens2004222172215106814
   PubMed Web of Science ®Google Scholar
• SchneiderMLerchMPapiriMMetabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlorthalodone treatment in hypertesnsive type 2 diabetesJ Hypertens199614669778762212
   PubMed Web of Science ®Google Scholar
• SicaDARationale for fixed-dose combination in the treatment of hypertension: the cycle repeatsDrugs2002624436211827559
   PubMed Web of Science ®Google Scholar
• SiepmanMRaoBRKirchWDisposition, elimination and haemodynamic effects of varapamil and trandolapril in patients with fatty liver diseaseClin Drug Invest19971437682
   Web of Science ®Google Scholar
• SowersJREffects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndromeNephrol Dial Transplant199510Suppl 95258643209
   PubMedGoogle Scholar
• SowersJBakrisGLAntihypertensive therapy and risk of type 2 diabetes mellitusN Engl J Med20003429697010738057
   PubMed Web of Science ®Google Scholar
• StrippoliGFMCraigMSchenaFPAntihypertensive agents for primary prevention of diabetic nephropathyJ Am Soc Nephrol20051630819116135776
   PubMed Web of Science ®Google Scholar
• SutterPMVettrWMetabolic effects of antihypertensive drugsJ Hypertens199513Suppl 4s11s17
   Google Scholar
• SweetmanSMartindale: the complete drug reference2005LondonPharmaceutical press Electronic version. Dantrolin sodium [online]. Accessed 2005 December 2. URL: http://www.medicinecomplete.com/mc/martindales
   Google Scholar
• TattiPPahorMByingtonRPOutcome results of fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDMDiabetes Care1998215976039571349
   PubMed Web of Science ®Google Scholar
• The BENEDICT GroupThe BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baselines groupControl Clin Trials2003244426112865039
   PubMedGoogle Scholar
• The Heart Outcome Prevention Evaluation Study InvestigatorsEffects of an angiotensine-converting-anzyme inhibitor, ramipril, on cardiovascular events in high-risk patientsN Engl J Med20003421455310639539
   PubMed Web of Science ®Google Scholar
• The Veratran study groupThe effects of verapamil SR trandolapril and their fix combination on 24-h blood pressure: the Veratran StudyAm J Hypertens19971049299160758
   PubMed Web of Science ®Google Scholar
• TopouchianJAsmarRSayeghFChanges in arterial structure and function under trandolapril-verapamil combination in hypertensionStroke19993010566410229744
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDSBMJ1998317703139732337
   PubMed Web of Science ®Google Scholar
• ViskoperRJCompagnoneDDiesRVerapamil and trandolapril alone and fixed combination on 24-hour ambulatory blood pressure profile of patients with moderate essential hypertesnsionCurr Ther Res Clin Exp19975834351
   Web of Science ®Google Scholar
• WaeberBTrails in isolated systolic hypertension: an updateCurr Hypertension Rep2003532936
   PubMed Web of Science ®Google Scholar
• WidimskyJThe fixed combination of verapamil SR/trandolaprilExpert Opin Pharmacother200015153511249535
   PubMedGoogle Scholar
• WisermanLRMcTavishDTrandolapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertensionDrugs199448171907525196
   PubMed Web of Science ®Google Scholar
• WildSRoglicGGreenAGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042710475315111519
   PubMed Web of Science ®Google Scholar
• World Health ReportSharing the FutureNeglected Global Epidemics: three growing threats in Report of World Health Organization, Geneva 20032003
   Google Scholar